In numerous solid tumor animal models, it has been proven that small molecule drugs or monoclonal antibodies directed against VISTA are beneficial to directly inhibiting Tregs and promoting the invasion and proliferation of tumor effector T cells as well as the secretion of cytokines, thereby enhancing the anti-tumor response (19). This evidence concerns the gene VSIR and neoplasm.